Issue link: https://www.e-digitaleditions.com/i/1496325
34 April 2023 Inhalation OINDP expertise including contract services Proveris® Laboratories offers orally inhaled and nasal drug product development (OINDP) expertise to pharmaceutical developers, including contract services employing new, innovative, in vitro techniques. ese include measuring plume front velocity and evapora- tion rate and quantifying deposition of inhaled drug products using human-realistic models. Employing in vitro approaches that are human-realistic can enable companies to make data-driven decisions and expe- dite product development and approval while saving time and resources. Learn more about these tech- niques and see data we have already published, avail- able on the Proveris website at www.proveris.com/ scientific-posters. Proveris Scientific Corporation US: +1 505 460-8822 contactus@proveris.com www.proveris.com Engineering design services MKON, LLC is a dedicated engineering design firm with extensive experience in computational fluid dynamics (CFD) and finite element analysis (FEA), as well as product and package design. e compa- ny's principal engineers have 28 patents that include injection-molded valve components and contain- ers, machine design improvements, CFD-based cre- ations and oxygen mitigation processes. MKON has a proven track record for identifying problems and engineering innovative solutions for our clients. MKON, LLC US: +1 908 240-4567 info@mkonllc.com www.mkonllc.com Bespoke inhaled formulation development i2c Pharmaceutical Services is a leading independent service provider to global pharma, medical technol- ogy and emerging companies for the development of inhaled formulations and efficient devices. i2c provides bespoke integrated services from ab initio development through clinical trials. i2c also offers Respitab ® ; this propellant-dispersible tablet is a cost-effective and innovative manufacturing platform that can facilitate transition to the next generation of pressurized metered dose inhalers (pMDIs). i2c Pharmaceutical Services UK: +44 2920 757865 www.i2cpharm.co.uk Plasma process for treating MDI canisters H&T Presspart offers a unique plasma process—man- ufactured under license from Portal Medical Ltd—for treating the internal surfaces of metered dose inhaler (MDI) canisters, which can help ensure the active drug content does not stick to the canister wall. is fluorocarbon polymerization (FCP) plasma treatment process can improve the surface energy performance of an MDI canister, which can enhance drug stability in formulations where interactions with the alumin- ium substrate can lead to product degradation and reduced shelf life. H&T Presspart UK: +44 1254 582233 blackburn@presspart.com www.presspart.com